Regorafenib (Stivarga) 40mg*28's | Bayer Germany Originator | GLT

Generic Information: Stivarga (Germany)

Stivarga is the originator brand of regorafenib, developed and marketed worldwide by Bayer of Germany. This German-origin presentation comes as a pack of 28 film-coated tablets, each containing 40 mg of regorafenib. Stivarga was the first medicine to show a survival benefit in previously treated metastatic colorectal cancer that had already progressed through multiple lines of standard chemotherapy and targeted therapy.

What Is Stivarga Used For?

Stivarga is approved for three advanced solid tumours. It is used in metastatic colorectal cancer that has progressed despite fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy plus anti-VEGF and, where relevant, anti-EGFR treatment. It is also indicated for gastrointestinal stromal tumour that has become resistant to imatinib and sunitinib, and for hepatocellular carcinoma that has progressed on sorafenib. In all three settings Stivarga is a later-line option for disease control.

How Does Regorafenib (Stivarga) Work?

Regorafenib is an oral inhibitor of multiple kinases involved in tumour growth and angiogenesis. It blocks the VEGF receptors 1, 2 and 3, TIE2, PDGFR-α and β, FGFR-1 and 2, KIT, RET, RAF-1 and BRAF. This broad inhibition suppresses both the signalling that makes cancer cells divide and the formation of new blood vessels that feed the tumour, which together slows disease progression in several cancer types.

Indications

The approved indications are metastatic colorectal cancer after standard therapy, imatinib- and sunitinib-refractory gastrointestinal stromal tumour, and sorafenib-refractory hepatocellular carcinoma. Stivarga should only be prescribed by an oncologist experienced in these diseases, and patients require assessment of liver function and blood pressure before and during treatment.

Dosage

The standard dose is 160 mg, taken as four 40 mg tablets once daily with a low-fat meal. Treatment is given in 28-day cycles consisting of 21 days on therapy followed by 7 days off. A 28-tablet pack supplies seven days of active dosing. Dose reductions to 120 mg or 80 mg daily are common when side effects such as hand-foot skin reaction or liver enzyme rises occur, and the dose may be escalated again once symptoms improve.

Side Effects

Common side effects include hand-foot skin reaction, diarrhoea, fatigue, hypertension, decreased appetite, and mucositis. More serious adverse events can include severe hepatotoxicity, haemorrhage, gastrointestinal perforation and cardiac ischaemia. Regular monitoring of liver enzymes, blood pressure and full blood counts is essential, and patients should promptly report skin peeling on the hands or feet, persistent diarrhoea, dark stools, or chest pain.

Storage

Store Stivarga tablets at room temperature in the original container, away from moisture, and out of the reach of children. Do not use past the expiry date shown on the pack.

Why Choose Stivarga Through GLT?

For institutions and overseas patients who specifically want the Bayer originator product, GLT can source genuine Stivarga from multiple markets. We help patients compare originator and licensed generic options so they can balance brand preference against cost, and we ship from a Hong Kong-licensed facility with transparent documentation.

How to Order

To order Stivarga (regorafenib) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We will confirm current availability, pricing and delivery to your country, and we ship from a Hong Kong-licensed facility.

FAQ

Is Stivarga the same as generic regorafenib? Yes — Stivarga is Bayer's originator brand, while the various domestic brands contain the same regorafenib molecule produced by other licensed manufacturers.

What is the dosing schedule? 160 mg once daily for 21 days, then a 7-day break, repeated every 28 days.

Do I need a prescription? Yes, Stivarga is a prescription-only oncology medicine and requires a valid prescription.